Sam Waksal (Robin Marchant/Getty Images)
September 9, 2021 09:36 AM EDTUpdated September 10, 06:07 AM
People
Startups

Ex­clu­sive: Prison and multi­bil­lion dol­lar buy­outs lat­er, Sam Wak­sal is all in on the biotech game, with some big-name back­ers

Amber Tong

Sam Wak­sal isn’t let­ting a five-year prison stretch for one of the most in­fa­mous in­sid­er trad­ing scan­dals in Wall Street his­to­ry stop him from do­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Lil­ly fi­nances new $500M biotech fund man­aged by a16z

Pfiz­er touts blad­der can­cer re­sults as first ad­vance­ment for some pa­tients 'in decades'

Ab­b­Vie writes off $3.5B on Cerev­el drug af­ter Phase 2 fail­ures

A service from the Financial Times